Tianjin Tianyao Pharmaceuticals (SHA:600488) received approval to amend the specification of its compound potassium hydrogen phosphate injection, according to a Shanghai bourse filing on Wednesday.
The supplementary application was approved after the drug, a phosphorus supplement for patients with hypophosphatemia, passed the regulator's quality and efficacy consistency evaluation.
The regulator approved that the drug's specification be changed to 2 milliliters, with 0.448 grams of potassium dihydrogen phosphate and 0.472 grams of dipotassium hydrogen phosphate.